$1.67 Billion is the total value of Frazier Life Sciences Management, L.P.'s 48 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HILLEVAX INC | $168,143,504 | +4.0% | 9,781,472 | 0.0% | 10.04% | -14.2% | ||
| KDNY | CHINOOK THERAPEUTICS INC | $166,956,377 | +66.0% | 4,345,559 | 0.0% | 9.97% | +36.9% | |
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $82,760,731 | -13.4% | 8,684,232 | 0.0% | 4.94% | -28.5% | |
| SNDX | SYNDAX PHARMACEUTICALS INC | $77,625,979 | -0.9% | 3,708,838 | 0.0% | 4.64% | -18.3% | |
| VRNA | VERONA PHARMA PLCsponsored ads | $62,243,538 | +5.3% | 2,944,349 | 0.0% | 3.72% | -13.2% | |
| TARS | TARSUS PHARMACEUTICALS INC | $32,300,613 | +43.8% | 1,787,527 | 0.0% | 1.93% | +18.6% | |
| ALPN | ALPINE IMMUNE SCIENCES INC | $30,693,582 | +33.2% | 2,985,757 | 0.0% | 1.83% | +9.8% | |
| KALV | KALVISTA PHARMACEUTICALS INC | $29,149,731 | +14.5% | 3,238,859 | 0.0% | 1.74% | -5.5% | |
| CRNX | CRINETICS PHARMACEUTICALS IN | $25,495,110 | +12.2% | 1,414,823 | 0.0% | 1.52% | -7.4% | |
| RVMD | REVOLUTION MEDICINES INC | $22,857,447 | +23.5% | 854,484 | 0.0% | 1.36% | +1.9% | |
| THESEUS PHARMACEUTICALS INC | $20,975,650 | +5.1% | 2,248,194 | 0.0% | 1.25% | -13.3% | ||
| ACAD | ACADIA PHARMACEUTICALS INC | $20,533,245 | +27.3% | 857,338 | 0.0% | 1.23% | +5.0% | |
| MRUS | MERUS N V | $19,654,792 | +43.1% | 746,479 | 0.0% | 1.17% | +18.1% | |
| ANAB | ANAPTYSBIO INC | $18,299,898 | -6.5% | 899,700 | 0.0% | 1.09% | -22.9% | |
| ENLIVEN THERAPEUTICS INC | $16,960,363 | -6.8% | 830,983 | 0.0% | 1.01% | -23.1% | ||
| CERE | CEREVEL THERAPEUTICS HLDNG I | $12,493,470 | +30.3% | 393,000 | 0.0% | 0.75% | +7.5% | |
| AUTL | AUTOLUS THERAPEUTICS PLCspon ads | $8,917,520 | +29.3% | 3,746,857 | 0.0% | 0.53% | +6.8% | |
| PRTA | PROTHENA CORP PLC | $8,733,012 | +40.9% | 127,900 | 0.0% | 0.52% | +16.3% | |
| NTLA | INTELLIA THERAPEUTICS INC | $8,306,234 | +9.4% | 203,684 | 0.0% | 0.50% | -9.8% | |
| ARVN | ARVINAS INC | $7,081,915 | -9.2% | 285,331 | 0.0% | 0.42% | -25.0% | |
| SLN | SILENCE THERAPEUTICS PLCads | $4,846,452 | -11.3% | 881,173 | 0.0% | 0.29% | -27.0% | |
| ADCT | ADC THERAPEUTICS SA | $3,541,115 | +10.3% | 1,647,030 | 0.0% | 0.21% | -9.4% | |
| ACRS | ACLARIS THERAPEUTICS INC | $2,741,589 | +28.2% | 264,377 | 0.0% | 0.16% | +5.8% | |
| NEWAMSTERDAM PHARMA COMPANY*w exp 11/22/202 | $1,045,696 | +13.6% | 500,333 | 0.0% | 0.06% | -7.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARCUTIS BIOTHERAPEUTICS INC | 7 | Q3 2023 | 17.0% |
| MIRUM PHARMACEUTICALS INC | 7 | Q3 2023 | 13.6% |
| PHATHOM PHARMACEUTICALS INC | 7 | Q3 2023 | 8.6% |
| KRYSTAL BIOTECH INC | 7 | Q3 2023 | 7.6% |
| SYNDAX PHARMACEUTICALS INC | 7 | Q3 2023 | 6.3% |
| VAXCYTE INC | 7 | Q3 2023 | 4.8% |
| CRINETICS PHARMACEUTICALS IN | 7 | Q3 2023 | 3.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 3.2% |
| TARSUS PHARMACEUTICALS INC | 7 | Q3 2023 | 2.5% |
| KALVISTA PHARMACEUTICALS INC | 7 | Q3 2023 | 2.1% |
View Frazier Life Sciences Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR/A | 2023-02-07 |
| 13F-HR | 2023-02-03 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-16 |
View Frazier Life Sciences Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.